Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02433873 · ClinicalTrials.gov registry record · NA
Prebiotic Effects of Isomalto-oligosaccharide
A NA study of Microbiota, sponsored by George Mason University.
- Completed
- Registry status
- NA
- Development phase
- 54
- Enrollment target
- 1
- Study location
NCT02433873: Completed NA study of Microbiota, sponsored by George Mason University.
NCT02433873 is a NA study of Microbiota that has completed, run by George Mason University. The registered enrollment target is 54 participants, below the 134-participant average among 10 other Microbiota trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02433873, a NA study of Microbiota, has completed, sponsored by George Mason University.
- COMPLETED
- Registry status
- NA
- Development phase
- 54 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this study is to evaluate the effect of an IMO nutritional supplement on gut microbiome, gut health, and body weight. Two formulations of the supplement will be evaluated; thus, there will be three study arms: Supplement A, Supplement B, and placebo. Stool samples will be analyzed for bacterial DNA. The gut bacterial DNA, body weight, and gut health data will be compared across supplement and placebo groups. Primary Aim 1: To evaluate the effect of the IMO supplement on gut bacterial abundance, diversity, and gene function across intervention and placebo groups, and across two doses of the intervention. Secondary Aim 1: To evaluate the effect of the IMO supplement on gut health across intervention and placebo groups, and across two doses of the intervention. Secondary Aim 2: To evaluate the effect of the IMO supplement on body weight across intervention and placebo groups, and across two doses of the intervention. 60 subjects, randomized to three arms (20 each: Supplement formula A, Supplement formula B or placebo) will take a daily dose of Supplement A, Supplement B, or placebo for 8 weeks. The supplement is a light syrup liquid. Ingredients that are in the supplement are: isomalto-oligosaccharide, water, mannitol, maltose, glucose, and glycerol. Ingredients that are in the placebo are: high maltose corn syrup (Satin Sweet™), water, and mannitol. Dose will be 500 mg during the first 4 weeks and then 1000 mg for second 4 weeks. Subjects will be instructed to take 500 mg/day of the supplement or placebo the first four weeks and 1000 mg/day of the supplement or placebo for the second four weeks. Subjects will be blinded as to whether they are receiving placebo or supplement. After screening and once enrolled, subject involvement includes visits to George Mason University, being weighed, dropping off stool samples, and completing a survey on gut health. Stool samples will be analyzed for bacterial DNA. The gut bacterial DNA, weight, and gut h
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Isomalto-oligosaccharide
Study Locations (1)
Virginia
- George Mason University - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2015-04 |
| Est. Completion | 2016-12 |
| Phase | NA |
What the finished NCT02433873 record still lists
NCT02433873 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 134-participant average among 10 other Microbiota trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Microbiota appearing as the primary indexed condition, and to 1 intervention - of which Isomalto-oligosaccharide is the first listed.
NCT02433873 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT02433873 about?
NCT02433873 is a clinical study titled "Prebiotic Effects of Isomalto-oligosaccharide". The primary purpose of this study is to evaluate the effect of an IMO nutritional supplement on gut microbiome, gut health, and body weight. Two formulations of the supplement will be evaluated; thus, there will be three study arms: Supplement A, Supplement B, and placebo. Stool samples will be anal...
What is the current status of trial NCT02433873?
This trial is currently completed. It is a NA study. The enrollment target is 54 participants. The study started on 2015-04. Estimated completion is 2016-12.
What conditions does trial NCT02433873 study?
This clinical trial studies the following conditions: Microbiota.
What interventions are being tested in trial NCT02433873?
The interventions under investigation include: Isomalto-oligosaccharide (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02433873?
This trial is sponsored by George Mason University, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02433873 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Microbiota
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02433873's enrollment target sits among peer trials
54 6th of 10 higher than 5 of 10 other Microbiota trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Microbiota trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Flourish: Exploring the Early Infant Gut Microbiome
RECRUITING · NA
-
Capillary Endoscopy Aspiration Catheter
RECRUITING · NA
-
Infant Restore: Efficacy of Microbiome Analysis and Education
ACTIVE NOT RECRUITING · NA
-
DASH INtervention to INvestigate the Gut
ACTIVE NOT RECRUITING · NA
-
Healthy Patients & Effect of Antibiotics
COMPLETED · NA
-
Assessing the Dose Response of a Lead Fiber Snack Prototype
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia